Categories: Social Responsibility

Rising Drug Costs: Are Pharmacy Benefits Managers to Blame?

Related media – Latest news

For many Americans, the rising tide of prescription drug prices seems like a relentless force, threatening to swamp family budgets and access to health care. While pharmaceutical companies often assume public responsibility, the web of influences on drug costs is much more intricate. Today we shine our spotlight on a critical, but typically hidden, player in this system: pharmacy benefit managers, or PBMs.

Rebecca Robbins, a leading investigative journalist specializing in pharmaceuticals for the New York Times, will take us on a deep dive into the world of PBMs. We will explore their role as intermediaries between drug manufacturers, insurers, pharmacies and, ultimately, patients. This complex dance can have a significant impact on how much you pay for your medications.

Our investigation will delve into how PBMs negotiate drug prices, formulate coverage lists (which determine which drugs are covered by insurance), and manage pharmacy networks. We will also explore potential conflicts of interest that can arise within this system and how these practices could contribute to the rising cost of prescription drugs.

By understanding the role of PBMs, we can gain a more complete picture of the factors that drive drug affordability. This knowledge is critical as policymakers and healthcare stakeholders work to create a more sustainable and equitable prescription drug market for all Americans.

You may also be interested in – Digital media
Anna Edwards

Recent Posts

The 8 industries that slashed water use and pollution output over a century

Introduction: A Century of Industrial TransformationOver the past hundred years, industrial activity has expanded at…

4 days ago

Why solitary arts activities do not reduce loneliness or improve health outcomes

A GP prescribing a painting class instead of an anxiolytic is a powerful image, and…

4 days ago

The anomaly of three-stock portfolios in modern finance

Under mean-variance portfolio theory, the optimal level of diversification today exceeds 300 stocks. The average…

4 days ago

therapy chatbots increase engagement without lasting symptom relief

The meta-analyses agree that mental health chatbots reduce symptoms of depression and anxiety. The effect…

5 days ago

The challenge of reaching socially excluded groups with museum fees

In 2001 the United Kingdom abolished admission charges at its national museums, and in 2002…

5 days ago

The limits of analysts’ two- and three-year earnings forecasts

Analysts' long-run earnings growth forecasts are less accurate than a naive model that simply predicts…

5 days ago